MA39770A - Protéines agonistes du récepteur trail monocaténaires - Google Patents
Protéines agonistes du récepteur trail monocaténairesInfo
- Publication number
- MA39770A MA39770A MA039770A MA39770A MA39770A MA 39770 A MA39770 A MA 39770A MA 039770 A MA039770 A MA 039770A MA 39770 A MA39770 A MA 39770A MA 39770 A MA39770 A MA 39770A
- Authority
- MA
- Morocco
- Prior art keywords
- receptor agonist
- agonist proteins
- trail
- chain trail
- trail receptor
- Prior art date
Links
- 229940123369 TRAIL receptor agonist Drugs 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 101100369993 Mus musculus Tnfsf10 gene Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 abstract 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 abstract 1
- 230000004931 aggregating effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
Abstract
La présente invention concerne des protéines agonistes du récepteur trail spécifique, des acides nucléiques codant pour ces dernières, et des méthodes de traitement d'un sujet ayant une maladie ou un trouble associé(e) au récepteur trail. Les protéines agonistes du récepteur trail de la présente invention comprennent trois domaines trail solubles et un fragment fc. Les protéines agonistes du récepteur trail sont sensiblement non agrégeantes et appropriées pour des applications thérapeutiques, diagnostiques et/ou de recherche.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461983152P | 2014-04-23 | 2014-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA39770A true MA39770A (fr) | 2015-10-29 |
Family
ID=53055121
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA039770A MA39770A (fr) | 2014-04-23 | 2015-04-23 | Protéines agonistes du récepteur trail monocaténaires |
MA045069A MA45069A (fr) | 2014-04-23 | 2015-04-23 | Protéines agonistes du récepteur trail monocaténaires |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA045069A MA45069A (fr) | 2014-04-23 | 2015-04-23 | Protéines agonistes du récepteur trail monocaténaires |
Country Status (37)
Country | Link |
---|---|
US (4) | US9908927B2 (fr) |
EP (2) | EP3134430B1 (fr) |
JP (2) | JP6523331B2 (fr) |
KR (2) | KR102079919B1 (fr) |
CN (2) | CN106459221B (fr) |
AR (1) | AR100168A1 (fr) |
AU (3) | AU2015249649B2 (fr) |
BR (1) | BR112016024515B1 (fr) |
CA (2) | CA3184067A1 (fr) |
CL (1) | CL2016002683A1 (fr) |
CR (1) | CR20160516A (fr) |
CY (1) | CY1120281T1 (fr) |
DK (1) | DK3134430T3 (fr) |
DO (1) | DOP2016000284A (fr) |
EC (1) | ECSP16089579A (fr) |
ES (1) | ES2672368T3 (fr) |
HR (1) | HRP20180950T1 (fr) |
HU (1) | HUE038914T2 (fr) |
IL (2) | IL248244B (fr) |
LT (1) | LT3134430T (fr) |
MA (2) | MA39770A (fr) |
MX (2) | MX2016013858A (fr) |
MY (1) | MY181986A (fr) |
NO (1) | NO2776305T3 (fr) |
PE (1) | PE20170299A1 (fr) |
PH (1) | PH12016502079B1 (fr) |
PL (1) | PL3134430T3 (fr) |
PT (1) | PT3134430T (fr) |
RS (1) | RS57153B1 (fr) |
RU (1) | RU2699285C2 (fr) |
SG (3) | SG10201806465TA (fr) |
SI (1) | SI3134430T1 (fr) |
TR (1) | TR201806912T4 (fr) |
TW (2) | TWI747178B (fr) |
UA (1) | UA118286C2 (fr) |
UY (1) | UY36095A (fr) |
WO (1) | WO2015164588A1 (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107709355B (zh) * | 2015-05-04 | 2021-09-14 | 阿珀吉尼科斯股份公司 | 单链cd40受体激动剂蛋白 |
AU2016342420B2 (en) * | 2015-10-23 | 2020-10-01 | Apogenix Ag | Single-chain LIGHT receptor agonist proteins |
AU2016341402B2 (en) * | 2015-10-23 | 2020-08-27 | Apogenix Ag | Single-chain GITR-receptor agonist proteins |
AU2016341409B2 (en) | 2015-10-23 | 2021-02-25 | Apogenix Ag | Single-chain CD27-receptor agonist proteins |
WO2017102010A1 (fr) * | 2015-12-17 | 2017-06-22 | Biontech Rna Pharmaceuticals Gmbh | Nouvelles protéines de fusion à cytokine |
CN109153711B (zh) * | 2016-03-01 | 2022-04-26 | 伊利诺伊大学理事会 | 具有降低的l-谷氨酰胺酶活性和增强的稳定性的l-天冬酰胺酶变体和融合蛋白 |
MX2018011219A (es) * | 2016-03-16 | 2019-01-10 | Merrimack Pharmaceuticals Inc | Trail diseñado por ingenieria para terapia de cancer. |
US10501744B2 (en) | 2016-05-04 | 2019-12-10 | Indiana University Research And Technology Corporation | Presentation of bioactive proteins |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
CN109641033A (zh) * | 2016-06-13 | 2019-04-16 | 梅里麦克制药股份有限公司 | 用基于trail的治疗剂或死亡受体激动剂选择和治疗患者的方法 |
EP3360898A1 (fr) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Molécules bispécifiques présentant une immunoréactivité par rapport à tnf-related apoptosis-inducing ligand receptor 2 et à cadherin 17 pour le traitement du cancer |
CA3106549A1 (fr) * | 2017-08-11 | 2019-02-14 | The Board Of Trustees Of The University Of Illinois | Variantes tronquees de la l-asparaginase de cochon d'inde et procedes d'utilisation |
WO2019178438A1 (fr) | 2018-03-15 | 2019-09-19 | Abbvie Inc. | Abbv-621 en combinaison avec des agents anticancéreux pour le traitement du cancer |
WO2019178433A1 (fr) | 2018-03-15 | 2019-09-19 | Abbvie Inc. | Abbv-621 en association avec des agents anticancéreux pour le traitement du cancer du pancréas |
EP4149964A2 (fr) | 2020-05-15 | 2023-03-22 | Apogenix AG | Modulateurs immunitaires multi-spécifiques |
WO2022248662A1 (fr) | 2021-05-28 | 2022-12-01 | Julius-Maximilians-Universität Würzburg | Molécules de liaison protéiques recombinantes |
WO2023088876A1 (fr) | 2021-11-16 | 2023-05-25 | Apogenix Ag | Modulateurs immunitaires multi-spécifiques |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7645700A (en) | 1999-10-07 | 2001-05-10 | Maxygen Aps | Single-chain antagonist polypeptides |
DE19963859A1 (de) | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
CA2314199A1 (fr) | 2000-07-21 | 2002-01-21 | Robert Simoneau | Puce c |
MXPA03005036A (es) | 2000-12-07 | 2003-09-05 | Lilly Co Eli | Proteinas de fusion glp-1. |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US7538088B2 (en) | 2002-04-26 | 2009-05-26 | California Institute Of Technology | Method for inhibiting angiogenesis by administration of the extracellular domain of D1-1 polypeptide |
DE102004014983A1 (de) | 2004-03-26 | 2005-10-20 | Univ Stuttgart | Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung |
US20060188498A1 (en) * | 2005-02-18 | 2006-08-24 | Genentech, Inc. | Methods of using death receptor agonists and EGFR inhibitors |
US8388962B2 (en) * | 2005-04-15 | 2013-03-05 | Rappaport Family Institute For Research In The Medical Sciences | Molecules and methods of using same for treating MCP-1/CCR2 associated diseases |
CA2606102C (fr) | 2005-04-26 | 2014-09-30 | Medimmune, Inc. | Modulation de la fonction d'effecteur d'anticorps par ingenierie de domaine "charniere" |
EP1894940A1 (fr) | 2006-08-28 | 2008-03-05 | Apogenix GmbH | Protéines de fusion de la superfamille TNF |
EP2176288B1 (fr) | 2007-07-10 | 2015-11-04 | Apogenix GmbH | Protéines de fusion collectines de la superfamille des tnf |
BRPI0913406A2 (pt) | 2008-06-03 | 2018-01-09 | Abbott Lab | imunoglobulinas de domínio variável duplo e usos das mesmas |
EP2310509B1 (fr) * | 2008-07-21 | 2015-01-21 | Apogenix GmbH | Molécules à une seule chaîne |
US20110287001A1 (en) | 2008-09-22 | 2011-11-24 | Tetralogic Pharmaceuticals | Method of treatment |
EP2379585A2 (fr) * | 2008-10-10 | 2011-10-26 | Anaphore, Inc. | Polypeptides qui se lient à trail-ri et trail-r2 |
ES2593049T3 (es) | 2009-01-09 | 2016-12-05 | Apogenix Ag | Proteínas de fusión que forman trímeros |
CA2750533A1 (fr) * | 2009-01-23 | 2010-07-29 | Biogen Idec Ma Inc. | Polypeptides fc stabilises avec une fonction effectrice reduite et procedes d'utilisation |
EP2516458A1 (fr) | 2009-12-22 | 2012-10-31 | Novartis AG | Protéine hybride tétravalente à région constante d'anticorps anti-cd-47 à utiliser en thérapie |
CA2795325A1 (fr) * | 2010-04-13 | 2011-10-20 | Medimmune, Llc | Echafaudages multimeriques a base de domaine de fibronectine de type iii |
US9764038B2 (en) * | 2011-12-23 | 2017-09-19 | Innate Pharma | Enzymatic conjugation of antibodies |
CN104640876A (zh) * | 2012-07-18 | 2015-05-20 | 阿珀吉尼科斯有限公司 | 包含CD95-Fc同种型的混合物的组合物 |
-
2012
- 2012-11-06 NO NO12790406A patent/NO2776305T3/no unknown
-
2015
- 2015-04-23 SG SG10201806465TA patent/SG10201806465TA/en unknown
- 2015-04-23 MA MA039770A patent/MA39770A/fr unknown
- 2015-04-23 AR ARP150101224A patent/AR100168A1/es active IP Right Grant
- 2015-04-23 KR KR1020167032819A patent/KR102079919B1/ko active IP Right Grant
- 2015-04-23 TW TW109106778A patent/TWI747178B/zh active
- 2015-04-23 PE PE2016002016A patent/PE20170299A1/es unknown
- 2015-04-23 SI SI201530223T patent/SI3134430T1/en unknown
- 2015-04-23 MA MA045069A patent/MA45069A/fr unknown
- 2015-04-23 CR CR20160516A patent/CR20160516A/es unknown
- 2015-04-23 RU RU2016145608A patent/RU2699285C2/ru active
- 2015-04-23 SG SG11201608767XA patent/SG11201608767XA/en unknown
- 2015-04-23 EP EP15721089.9A patent/EP3134430B1/fr active Active
- 2015-04-23 WO PCT/US2015/027270 patent/WO2015164588A1/fr active Application Filing
- 2015-04-23 TR TR2018/06912T patent/TR201806912T4/tr unknown
- 2015-04-23 DK DK15721089.9T patent/DK3134430T3/en active
- 2015-04-23 MX MX2016013858A patent/MX2016013858A/es active IP Right Grant
- 2015-04-23 ES ES15721089.9T patent/ES2672368T3/es active Active
- 2015-04-23 EP EP18155146.6A patent/EP3366699A1/fr not_active Withdrawn
- 2015-04-23 CA CA3184067A patent/CA3184067A1/fr active Pending
- 2015-04-23 BR BR112016024515-6A patent/BR112016024515B1/pt active IP Right Grant
- 2015-04-23 HU HUE15721089A patent/HUE038914T2/hu unknown
- 2015-04-23 JP JP2016564068A patent/JP6523331B2/ja active Active
- 2015-04-23 CN CN201580031858.7A patent/CN106459221B/zh active Active
- 2015-04-23 TW TW104113087A patent/TWI683825B/zh active
- 2015-04-23 AU AU2015249649A patent/AU2015249649B2/en active Active
- 2015-04-23 CA CA2946402A patent/CA2946402C/fr active Active
- 2015-04-23 PL PL15721089T patent/PL3134430T3/pl unknown
- 2015-04-23 UA UAA201611802A patent/UA118286C2/uk unknown
- 2015-04-23 UY UY0001036095A patent/UY36095A/es active IP Right Grant
- 2015-04-23 KR KR1020197035100A patent/KR20190135546A/ko not_active Application Discontinuation
- 2015-04-23 SG SG10202111785VA patent/SG10202111785VA/en unknown
- 2015-04-23 PT PT157210899T patent/PT3134430T/pt unknown
- 2015-04-23 LT LTEP15721089.9T patent/LT3134430T/lt unknown
- 2015-04-23 CN CN202010767219.XA patent/CN111718424A/zh active Pending
- 2015-04-23 RS RS20180450A patent/RS57153B1/sr unknown
- 2015-04-23 US US14/694,358 patent/US9908927B2/en active Active
- 2015-04-23 MY MYPI2016703814A patent/MY181986A/en unknown
-
2016
- 2016-10-07 IL IL248244A patent/IL248244B/en active IP Right Grant
- 2016-10-19 DO DO2016000284A patent/DOP2016000284A/es unknown
- 2016-10-19 PH PH12016502079A patent/PH12016502079B1/en unknown
- 2016-10-21 CL CL2016002683A patent/CL2016002683A1/es unknown
- 2016-10-21 MX MX2019013587A patent/MX2019013587A/es unknown
- 2016-11-23 EC ECIEPI201689579A patent/ECSP16089579A/es unknown
-
2018
- 2018-02-02 US US15/887,509 patent/US20180222962A1/en not_active Abandoned
- 2018-05-25 CY CY20181100568T patent/CY1120281T1/el unknown
- 2018-06-19 HR HRP20180950TT patent/HRP20180950T1/hr unknown
- 2018-11-30 AU AU2018271369A patent/AU2018271369B2/en active Active
-
2019
- 2019-04-24 JP JP2019082671A patent/JP6714751B2/ja active Active
-
2020
- 2020-02-11 IL IL272612A patent/IL272612A/en unknown
- 2020-03-30 AU AU2020202247A patent/AU2020202247A1/en not_active Abandoned
- 2020-08-14 US US16/993,569 patent/US20210040178A1/en not_active Abandoned
-
2023
- 2023-07-14 US US18/352,769 patent/US20240174731A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019013587A (es) | Proteinas agonistas del receptor del ligando que induce la apoptosis relacionada con el factor de necrosis de tumor de cadena individual. | |
MX2017014140A (es) | Proteinas agonistas receptoras cd40 de cadena simple. | |
IL278014A (en) | Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use | |
IL251194A0 (en) | Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria | |
HK1254755A1 (zh) | 抗-肌肉生長抑制因子抗體、包含變體fc區的多肽及使用方法 | |
PH12016501644A1 (en) | Binding proteins and methods of use thereof | |
MX2017003847A (es) | Proteinas biespecificas activables por proteasas. | |
MX2018001787A (es) | Proteinas de fusion del ligando de la proteina relacionada con el receptor de factor de necrosis tumoral inducido por glucorticoides (gitrl) y usos de las mismas. | |
MX2017016502A (es) | Anticuerpos contra cd40 con actividad agonista mejorada. | |
AR102879A1 (es) | Métodos para el tratamiento de tumores cerebrales | |
UA117045C2 (uk) | Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосування | |
MX2017014397A (es) | Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn). | |
IL254242A0 (en) | Dual signaling fusion proteins and methods of using them to treat diseases | |
MX2016012219A (es) | Agonistas de receptor fgf21 y usos del mismo. | |
MX2017011991A (es) | Terapia virica con una combinacion de anticuerpos. | |
MX2019013124A (es) | Proteinas de fusion de inhibidor de tripsina urinaria (uti). | |
EP3227681A4 (fr) | Anticorps anti-acétaminophène et produits d'addition acétaminophène-protéine | |
EA201992348A1 (ru) | АНТИГЕН-СВЯЗЫВАЮЩИЕ БЕЛКИ, ВЗАИМОДЕЙСТВУЮЩИЕ С Jagged1 | |
WO2016007919A3 (fr) | Fragments d'anticorps pour détecter un cancer et méthodes d'utilisation | |
MX2016015280A (es) | Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso. | |
EP3925979A3 (fr) | Protéines de fusion fgfr-tacc et utilisations associées | |
NZ761611A (en) | Single-chain trail-receptor agonist proteins | |
SG11201703624PA (en) | Compounds for the diagnosis or treatment of disorders associated with protein or peptide oligomers | |
EA202092450A2 (ru) | Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей |